Cervical Cancer
A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physicians Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20) (MK2870-020-00)
- Details
ClinicalTrials.gov ID:
NCT06459180
Diagnosis Type:
NA
USOR Number:
- Address
,
P: